Peptide LibraryEtelcalcetide dosage in published studies and labels
These are the doses used for Etelcalcetide in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Etelcalcetide has an FDA-approved human dosage. Parsabiv for secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis starts at 5 mg as an intravenous bolus three times a week at the end of dialysis. The maintenance dose is set by PTH and calcium levels, from 2.5 mg to 15 mg three times a week.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 2.5–15 mg three times weekly at the end of hemodialysis |
| Route | Intravenous |
| Frequency | Three times weekly, at the end of hemodialysis |
| Duration studied | Continuous |
| Titration | Increase in 2.5 mg or 5 mg steps no more often than every 4 weeks, up to 15 mg, while corrected calcium is normal and PTH is above target. Lower or pause for low PTH or low calcium. |
| Evidence level | FDA Approved |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| FDA label — Parsabiv, secondary hyperparathyroidismFDA-approved label · FDA prescribing information | Adults with chronic kidney disease on hemodialysis with secondary hyperparathyroidism | Start 5 mg; maintenance 2.5–15 mg by PTH and corrected serum calcium | Intravenous bolus into the venous line of the dialysis circuit during or after rinse back | Three times weekly, at the end of hemodialysis | Continuous | PTH within target with normal serum calcium | PARSABIV (etelcalcetide) injection — FDA prescribing information, DailyMed |
Where sources disagree
- Parsabiv is given only at the end of a hemodialysis session; missed sessions are not made up. It has not been studied in, and is not recommended for, people with CKD who are not on hemodialysis.
- The label says to stop Parsabiv and treat low calcium if corrected serum calcium falls below 7.5 mg/dL or symptoms of hypocalcemia appear.